J O I N   O U R   M O N T H L Y   R E P O R T   &   U P D A T E   A L E R T S !  
.
   | Objective & Independent Equity Research
About Us Research Reports EquityNet in the News Affiliates Blog Contact Us
.

American Jianye Greentech Holdings, Ltd.
OTCBB : AJGH
Recommendation: BUY
6 Mo. Price Target: $2.12
FEATURED REPORT

Biostar Pharmaceuticals, Inc.
OTCBB: BSPM
Recommendation: STRONG BUY
12 Mo. Price Target: $9.13
FEATURED REPORT

Huifeng Bio-Pharmaceutical Technology, Inc
OTCBB: HFGB
Rating: Spec Buy
12 Mo. Price target $2.37
FEATURED REPORT

SkyPeople Fruit Juice, Inc.
AMEX: SPU
Rating: BUY
12 mo. Price Target: $13.29
FEATURED REPORT

Welcome to EquityNet Research.  Here you will find a frequently updated list of the latest equity research, reviews and news you need to know when searching for stocks and company information. If you haven't done so already, take a minute to subscribe to our Monthly Report and Update Alerts!

EquityNet Research was formed in January 1999 to provide the investing public with professional, independent, objective research on under-followed public companies.


Is Analyst Coverage Necessary?
Take a look at these facts:

  • 70.9% in an Investopedia.com survey said that "a company that hires a legitimate fee-based research firm is making a positive statement about its investment potential."

  • According to a survey by Charles Schwab & Co. reported in the NY Times, an astonishing 78% of active stockholders now "value research from independent firms over analysis by Wall Street firms with financial ties to the companies they are rating..."

So why is independent research so important? It is much more than simply telling the story from an outside pair of eyes (though it does that). Independent research provides a benchmark by which potential investors can gauge a company's fair value, eliminating such extraneous factors as wars, political uncertainty, market-maker manipulation, etc. And perhaps most importantly, it is a statement by management to current shareholders and investors that, "We have the confidence in our business model to pay an independent analyst to perform a fair, accurate valuation on our stock. Not only do we not have anything to hide, we are sure the market will share our enthusiasm once all the facts are elicited."

BUYSIDE Magazine
March 2005

While some issuer-paid research firms keep their analysts on an independent contractor basis, Sherman Oaks, CA based EquityNet Research has revolved around the idea that the principals of the company think a stock is worth covering, it's worth them covering it on their own....

 

Abbott Laboratories completes Piramel unit buyout
Wed, 08 Sep 2010 11:28:17 UTC - [AP] - Abbott Laboratories said Wednesday it completed the buyout of Piramel Healthcare Ltd. s domestic health care business for $3.8 billion.

China Mobile falls as Vodafone sells $6.5 billion stake
Wed, 08 Sep 2010 11:25:13 UTC - [Reuters] - China Mobile shares fell the most in a year after Vodafone Group Plc sold its stake in the company for $6.5 billion, nearly double what it paid, but analysts expect the stake sale to have no major impact on the Chinese firm.

UPDATE - Shanghai Pharma to raise $1.2 bln in HK to fund M&A
Wed, 08 Sep 2010 10:45:51 UTC - [at Reuters] - * Shanghai Pharmaceuticals to sell 25 percent stake * Will use proceeds to acquire rivals, sales networks * Shares suspended since Tuesday pending announcement

Buyout Shops Said to Plan to Build Irish Bank on EBS
Wed, 08 Sep 2010 10:41:50 UTC - [at New York Times] - J.C. Flowers & Co. and three other bidders for Ireland s EBS Building Society may buy and merge several lenders to create a new competitor to the country s biggest banks, two people familiar with the situation said.
     Copyright © 2010 EquityNet, Research. All rights reserved. Contact Us | Disclosure | Privacy Statement